论文部分内容阅读
对63例原发性子宫颈癌患者血清免疫抑制酸性蛋白(IAP)和鳞状细胞癌抗原(SCCAg)进行研究。63例中鳞癌53例(84％);腺癌10例(16％)。66例正常绝经后妇女为对照组。治疗前采血贮藏于—20℃保存,采用放免扩散法测定。IAP>613μg/ml为阳性,SCCAg超过2.5ng/ml为阳性。 在子宫颈癌患者中IAP血清值(均值630μg/ml,范围290～1150)高于对照组(均值290μg/ml,范围135～775)(P<0.01)具有统计学意义,其阳性率为50.7％。宫颈癌患者中SCC高于2.5ng/ml的占73％,对照组仅有6％为阳性。宫颈癌患者的sCCAg
63 patients with primary cervical cancer serum immunosuppressive acid protein (IAP) and squamous cell carcinoma antigen (SCCAg) were studied. 63 cases of squamous cell carcinoma in 53 cases (84%); adenocarcinoma in 10 cases (16%). 66 cases of normal postmenopausal women as control group. Pre-treatment blood collection stored at -20 ℃, measured by radioimmunoassay. IAP> 613μg / ml is positive, SCCAg more than 2.5ng / ml is positive. In cervical cancer patients, IAP serum levels (mean 630 μg / ml, range 290-1150) were significantly higher than those of the control group (mean 290 μg / ml, range 135-775) (P <0.01) %. In cervical cancer patients SCC higher than 2.5ng / ml accounted for 73%, only 6% of the control group was positive. Cervical cancer patients with sCCAg